UroGen Pharma 株価情報 (NASDAQ: URGN)

最新ニュース UroGen Pharma (NASDAQ:URGN) 株価情報

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Ltd

If you've ever opened a medical bill and wondered how a ten-minute visit costs more than your rent, <a href="https://www.benzinga.com/news/25/04/44885628/mark-cuban-says-health-insurance-shouldnt-exist-you-dont-have-to-grab-every-nickel-when-its-the-health-of-the-entire-country-at-stake">Mark Cuban's right there with you</a>—only louder, bolder, and a lot less polite about it.
Cuban may have made his billions in tech and sports, but in recent years, he's shifted his sights toward America's other broken empire: healthcare. And during an <a href="https://www.offcall.com/learn/podcast/mark-cuban-interview-how-shark-tank-star-and-cost-plus-drugs-ceo-would-fix-healthcare">April episode of the "How I Doctor" podcast</a> hosted by Dr. Graham Walker, he made it clear he isn't here to fix it gently.
"Insurance companies are the worst of the worst of the worst of the worst of the worst," Cuban said. "If you look at how insurance plans are designed, it should be criminal."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
He wasn't warming up. He was just getting started.
Cuban, who co-founded <a href="https://www.benzinga.com/news/25/04/44658207/mark-cuban-says-cost-plus-drugs-faces-price-hike-threat-tariffs-would-force-us-to-pass-costs-directly-to-consumers">Cost Plus Drugs in 2022</a> to tackle inflated prescription prices, is now taking aim at what he sees as the system's core problem: the way health insurance shifts all the risk onto the people doing the care—and the people needing it.
"If they design a high-deductible health plan and they make it available to somebody with a take-home pay of $25,000, and there's a deductible of $5,000, [doctors] are screwed," he said. "Even if the patient is broke as a joke and doesn't have two nickels to rub together, you still have to care for them."
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
And once the patient leaves? That debt becomes the doctor's problem, too. "Now you're the one also responsible for figuring out a payment methodology—if there is one."
Dr. Walker, co-founder of Offcall—a platform built to expose pay gaps, reduce burnout, and fight bureaucracy—asked Cuban what he would do if he were in charge. Cuban didn't flinch. His proposals range from common sense to scorched-earth:
<ul class="wp-block-list">
<li>Make medical school free. "$24 billion is nothing," Cuban said. "But it changes the dynamics considerably to improve the quality of care."</li>
<li>Pay doctors more. "If I'm getting a heart transplant, I want that motherf&#x2A;&#x2A;&#x2A;ing doctor to make $10,000," he said. "So they're paying attention and not worried about the next heart transplant or the patient with a boo-boo."</li>
<li>Ditch prior authorizations. "They're designed to drive doctors crazy," he said. "But if you're making an extra $400 million just by stalling, you're going to keep doing it."</li>
</ul>
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
But Cuban's rage isn't limited to insurance plans. He also went after hospitals that charge "facility fees" for things that make no sense and the "arbitrage" tactics used by private equity to squeeze doctors dry.
"In healthcare, that $4.9 trillion—wherever anybody can arbitrage whatever they can out of the system—that's exactly what they are going to do," he said.
Cuban's solution? Put power back into the hands of physicians. Create direct-care networks. Cut out the middlemen. Build a virtual hospital if you have to. <a href="https://www.benzinga.com/personal-finance/25/03/44178175/elon-musk-wants-to-know-why-healthcare-costs-so-much-mark-cuban-gives-him-7-brutal-reasons-why-ceos-like-him-are-making-it-worse">Just stop pretending the system works</a>.
Because, as he put it: "This whole conversation is about how can we get doctors to be able to golf on Wednesdays like they used to."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Mark Cuban Blasts Health Insurance Companies As 'The Worst Of The Worst' — Says It Should Be Criminal To Charge $5K Deductibles To People Making $25K

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.09% on an annualized basis producing an average annual return of 9.4%. Currently, Nike has a market capitalization of $92.25 billion. 
Buying $1000 In NKE: If an investor had bought $1000 of NKE stock 20 years ago, it would be worth $6,052.38 today based on a price of $62.37 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747352719_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Nike Stock In The Last 20 Years

Kohl's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) ("Kohl's") announced today the pricing of its previously announced private offering (the "Offering") of $360 million aggregate principal amount of 10.000% senior secured notes due 2030 (the "Notes"). The Notes will be guaranteed by Kohl's subsidiaries. Certain guarantees will be secured by, among other collateral, 11 distribution centers and e-commerce fulfillment facilities, which will be held in a newly-formed holding company. The Offering is expected to close on May 30, 2025, subject to customary closing conditions.
Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Offerings

Kohl's Announces The Pricing Of Its Previously Announced Private Offering Of $360M Aggregate Principal Amount Of 10.000% Senior Secured Notes Due 2030

FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) has outperformed the market over the past 10 years by 12.87% on an annualized basis producing an average annual return of 23.61%. Currently, FTAI Aviation has a market capitalization of $12.05 billion. 
Buying $100 In FTAI: If an investor had bought $100 of FTAI stock 10 years ago, it would be worth $815.66 today based on a price of $117.45 for FTAI at the time of writing.
<h3>FTAI Aviation's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747351817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTAI

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 20 years by 7.51% on an annualized basis producing an average annual return of 15.83%. Currently, CoStar Group has a market capitalization of $32.08 billion. 
Buying $1000 In CSGP: If an investor had bought $1000 of CSGP stock 20 years ago, it would be worth $19,117.65 today based on a price of $76.05 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747350911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

Here's How Much $1000 Invested In CoStar Group 20 Years Ago Would Be Worth Today

Gold rush is back, and instead of miners and pickaxes, its hedge funds and billion-dollar spreadsheets. 
Ray Dalio&#8217;s Bridgewater Associates <a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">opened a fresh $318.8 million position</a> in SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) during the first quarter of 2025, as per a new 13F filing with the SEC. For the world&#8217;s largest hedge fund, it&#8217;s not mere portfolio adjustment, it&#8217;s a shiny declaration.
Dalio, a long-time outspoken proponent of &#8220;hard money,&#8221; recently doubled down on his opinion during a presentation at Abu Dhabi Finance Week. Forecasting a coming &#8220;debt money problem&#8221; due to hyperborrowing by the U.S., China and virtually every large economy other than Germany, Dalio expressed his fondness for the likes of gold and Bitcoin over conventional debt vehicles.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45235676/exclusive-expert-explains-how-this-gold-etf-lets-you-physically-hold-your-wealth-and-why-investors-are-quietly-rushing-in">Exclusive: Expert Explains How This Gold ETF Lets You Physically Hold Your Wealth And Why Investors Are Quietly Rushing In</a>
He&#8217;s not the only one embracing this golden gospel. No, institutional investors are flocking to the yellow metal at a furious clip — 1,187 GLD shares were added last quarter. BlackRock, Goldman Sachs and UBS all bulled up their gold ETFs with positions in GLD, according to Quiver Quantitative.
<h1 class="wp-block-heading">GLD Is The Standard-Bearer—But Not The Only Game In Town</h1>
GLD might be the <a href="https://www.benzinga.com/etfs">gold ETF heavyweight</a> champion, but it&#8217;s not alone in the ring. Those interested in playing with bullion without keeping it under the mattress can consider:
iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>): Inexpensive and popular with good liquidity, perfect for long-term investors who prefer fees on the lean side (expense ratio is 0.25%).
SPDR Gold MiniShares Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLDM#NYSE">GLDM</a>): It&#8217;s like GLD&#8217;s less expensive cousin and it has a smaller expense ratio (0.1%).
Goldman Sachs Physical Gold ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/AAAU#BATS">AAAU</a>): Supported by physical gold and Goldman&#8217;s influence, it&#8217;s picking up among newer gold bugs.
<h2 class="wp-block-heading">The Golden Fuel</h2>
Aside from hedge fund mania, there is a macro muscle driving the gold rally. Central banks have purchased more than 1,000 metric tons of gold per year since Russia&#8217;s invasion of Ukraine in 2022, twice the amount of the previous decade, per a Reuters report from April. 
Why? Central banks are diversifying out of the dollar and hedging against geopolitical risk and Trump-fiscal pyrotechnics.
<h1 class="wp-block-heading">The Bigger Picture</h1>
Dalio puts it best: debt, money and the economy are only one of five epic forces remaking the world. The others — domestic political strains, foreign geopolitical conflicts, acts of nature, and technological innovation — are all lighting up red or amber. Gold, in such a scenario, is not simply a safety net. It&#8217;s a statement.
So, whether you're a hedge fund titan, a cautious retail investor or someone who just likes a little shine in their portfolio, the message is clear: in an age of debt and disruption, gold isn't going out of style anytime soon.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45448912/lazard-transforms-mutual-fund-into-ieq-etf-amid-rising-demand-for-international-stocks">Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

AAAU

GLDM

Move Over Miners, Hedge Funds Are The New Gold Diggers ... Ray Dalio, BlackRock, Goldman Sachs, Others Stake Claims In GLD

The Port of Los Angeles, the busiest in the Western Hemisphere, has seen a 35% drop in cargo volume compared to the same period last year, according to Gene Seroka, the port&#8217;s executive director. The drop reflects the harsh impact of recent tariffs imposed by President Donald Trump&#8217;s administration.&nbsp;
<h2 class="wp-block-heading">Pushback on Fox News</h2>
The economic fallout from these tariffs sparked a heated exchange on the recent Fox News &#8220;The Five&#8221; <a href="https://x.com/JessicaTarlov/status/1920159291530485767">show</a>. One of the hosts, Jessica Tarlov, argued that despite the administration&#8217;s attempts to downplay the impact, the consequences are already being felt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The executive director of the port of Los Angeles talked about how the port is now down 35% in terms of volume. He says truckers and dockworkers are going to be laid off. It&#39;s incredible the Trump Administration is acting like this isn't a big deal. <a href="https://t.co/wOt3ADHHtq">pic.twitter.com/wOt3ADHHtq</a>
&mdash; Jessica Tarlov (@JessicaTarlov) <a href="https://twitter.com/JessicaTarlov/status/1920159291530485767?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
&#8220;Prices are already going up,&#8221; Tarlov said, highlighting layoffs at a Mack truck plant in Pennsylvania and rising costs hitting major companies like Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>). She pointed to the executive director of the Port of Los Angeles, who, besides reporting a 35% drop in cargo volume, also warned that truckers and dock workers could soon face significant layoffs.
When co-hosts Jeanine Pirro and Greg Gutfeld tried to push back, suggesting that there&#8217;s always talk about layoffs but they never happen, Tarlov shot back, &#8220;It&#8217;s <a href="https://www.benzinga.com/markets/equities/25/04/44642355/trumps-25-auto-tariffs-spark-stellantis-layoffs-gm-expansion-uaws-shawn-fain-calls-job-cuts-completely-unnecessary">not true that it doesn&#8217;t happen</a>&#8230; These are real consequences.&#8221;
As she wrote in a <a href="https://x.com/JessicaTarlov/status/1920159291530485767">post on X</a> on Wednesday, &#8220;It&#8217;s incredible the Trump Administration is acting like this isn't a big deal.&#8221;
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
She argued that countries are finding ways to adapt to the tariffs, noting that Canada has increased its exports to other markets by 25% since the tariffs were introduced. Co-host Jesse Watters challenged this claim, insisting that Canada&#8217;s economy is struggling, but Tarlov stood firm, saying, &#8220;I do look at the statistics all day.&#8221;
She also cited comments from Treasury Secretary Scott Bessent, who, at the time, acknowledged that the U.S. hadn&#8217;t had direct trade talks with China, despite Trump&#8217;s claims to the contrary. Tarlov noted that Bessent told Congress the administration has engaged with 17 countries about trade, but not China, which remains the critical player in the ongoing dispute.
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Impact on Workers and Local Businesses</h2>
For workers like Charlie Camacho, a longshore worker whose family has worked at the port for three generations, the decline is already hitting home. Speaking to <a href="https://www.npr.org/2025/05/07/nx-s1-5389955/los-angeles-port-tariffs">NPR</a>, Camacho described the struggle to find work as container volumes plummet. &#8220;Less volume of cargo containers means less work for us,&#8221; he said. &#8220;We feel it, we definitely feel it.&#8221;
It&#8217;s not just dockworkers feeling the squeeze. Small business owners like Frank Groves, who sells gloves and safety gear to port workers, have also seen their income collapse. Groves told NPR that his business is down nearly 75% in recent weeks. &#8220;No sales at all really. If they aren&#8217;t working, I don&#8217;t make money,&#8221; he said.
Even if the tariffs were to be lifted soon, some experts say the damage could be long-lasting. Former Los Angeles City Harbor Commissioner Diane Middleton warned that supply chains can&#8217;t be rebuilt overnight. &#8220;You don&#8217;t just have ships lined up like taxi cabs,&#8221; she told NPR, noting that the logistical challenges of reversing these disruptions could linger for months, if not years. &#8220;You have to reserve vessels. You have to specify a time. Once you&#8217;ve cut all that off, you can&#8217;t bring it back in a minute.&#8221;
As the debate over tariffs continues, it's clear that the <a href="https://www.benzinga.com/personal-finance/25/05/45183970/behind-the-empty-docks-how-trumps-145-tariffs-are-gutting-u-s-supply-chains">economic fallout</a> is already hitting American businesses and workers hard, despite the administration&#8217;s attempts to downplay the impact.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

MSFT

'It's Incredible The Trump Administration Is Acting Like This Isn't A Big Deal,' Says Fox Host As LA Port Volume Drops 35% And Layoffs Loom

Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) has outperformed the market over the past 15 years by 4.79% on an annualized basis producing an average annual return of 16.71%. Currently, Extra Space Storage has a market capitalization of $31.53 billion. 
Buying $1000 In EXR: If an investor had bought $1000 of EXR stock 15 years ago, it would be worth $10,597.72 today based on a price of $148.58 for EXR at the time of writing.
<h3>Extra Space Storage's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747350014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 12.94%. Currently, Home Depot has a market capitalization of $376.37 billion. 
Buying $100 In HD: If an investor had bought $100 of HD stock 10 years ago, it would be worth $337.04 today based on a price of $378.63 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747349113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Home Depot 10 Years Ago Would Be Worth This Much Today

Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $6.33 million in sales this quarter. This is a 42.18 percent decrease over sales of $10.95 million the same period last year.

Earnings

SKYQ

Sky Quarry Q1 EPS $(0.16) Down From $(0.15) YoY, Sales $6.33M Down From $10.95M YoY

It&#8217;s been a roller coaster year for Wall Street as investors revise expectations during a period of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">rapidly changing policy announcements</a> in the White House. While markets turned bearish in March and April as the Trump Administration threatened tariffs on several U.S. trade partners, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) retraced some of its losses as the administration backed off some of its policy commitments and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45376487/wall-street-edges-higher-as-inflation-cools-nasdaq-100-hits-10-week-highs">economic indicators look promising</a>.
Stephanie Link, chief investment officer and portfolio manager at Hightower Advisors, is optimistic about the market&#8217;s prospects if tariff concerns can be averted.
&#8220;I think the biggest surprise is that the Atlanta Fed [GDPNow] is at 2.3% in the face of everything,&#8221; Link wrote on Thursday. &#8220;Consumer continues to spend — Walmart is proof of that. Labor market remains solid and inflation is coming down albeit slowly. EPS up 12% is impressive as well. Get through tariffs and we'll start to focus on more positive things — lower taxes and deregulation.&#8221;
Link noted two contrarian plays she is bullish on as 2025 enters its second half. She called Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) her &#8220;favorite stock for 2025&#8221; amid the company&#8217;s turnaround under new leadership. While the Arlington, Virginia-based company&#8217;s shares have fallen from all-time highs due to regulatory woes and safety concerns, its stock is up over 20% in 2025.
Link also highlighted private equity giant KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) as a firm benefiting from several positive trends.
&#8220;Added KKR this past week [with] the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth,&#8221; Link said.
She noted Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>), Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) and Rockwell Automation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as other infrastructure plays.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Photo: Shutterstock

Equities

Hedge Funds

Exclusives

'My Favorite Stock For 2025,' Says Portfolio Manager, Who Also Notes Two Contrarian Plays During Growth Optimism

Femto Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) reported quarterly losses of $(2.50 thousand) per share. The company reported $141.20 thousand in sales this quarter.

FMTO

Femto Technologies Q1 EPS $(2.50K), Sales $141.20K

Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.

KTTA

Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY

Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) reported quarterly losses of $(1.40) per share. This is a 87.93 percent increase over losses of $(11.60) per share from the same period last year.

VINC

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $2.00 million which missed the analyst consensus estimate of $3.38 million by 40.62 percent. This is a 94.52 percent decrease over sales of $36.60 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) reported quarterly losses of $(0.08) per share. This is a 75.76 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.10 thousand in sales this quarter. This is a 75.34 percent decrease over sales of $170.73 thousand the same period last year.

SHOT

Safety Shot Q1 EPS $(0.08) Up From $(0.33) YoY, Sales $42.10K Down From $170.73K YoY

Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) reported quarterly losses of $(1.64) per share. This is a 82.25 percent increase over losses of $(9.24) per share from the same period last year. The company reported $322.00 thousand in sales this quarter. This is a 37.23 percent decrease over sales of $513.00 thousand the same period last year.

MNTS

Momentus Q1 EPS $(1.64) Up From $(9.24) YoY, Sales $322.00K Down From $513.00K YoY

Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported $8.01 million in sales this quarter. This is a 29.70 percent increase over sales of $6.18 million the same period last year.

FKWL

Franklin Wireless Q3 EPS $(0.05) Up From $(0.10) YoY, Sales $8.01M Up From $6.18M YoY

GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the same period last year.

Earnings Beats

GTBP

GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported quarterly losses of $(0.05) per share. This is a 75 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.07 thousand in sales this quarter. This is a 99.55 percent decrease over sales of $1.13 million the same period last year.

HCWB

HCW Biologics Q1 EPS $(0.05) Up From $(0.20) YoY, Sales $5.07K Down From $1.13M YoY

Press Releases

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Comments

UroGen Pharma

ニュース

最新ニュース UroGen Pharma (NASDAQ:URGN) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル